Company intelligence
Care Pathway Consulting
Rethinking Care Pathways for Planetary and Human Health
About Care Pathway Consulting
We help healthcare systems and life science companies reduce emissions by redesigning how care is delivered. Our work is grounded in evidence, focused on impact, and driven by the belief that what’s good for the planet can also be good for patients.
Verified activity
Signals from Care Pathway Consulting
9 published signals
Legal & Regulatory
Care Pathway Consulting noted that transposition by 22 December 2027 is required.
Reported by Frederik Dam van Deurs
Legal & Regulatory
Care Pathway Consulting noted that the revised Urban Wastewater Treatment Directive obliges pharma and cosmetics manufacturers to fund at least 80% of urban micropollutant removal by the end of 2028.
Reported by Frederik Dam van Deurs
Legal & Regulatory
Care Pathway Consulting noted that the EU Pharma Package, due autumn 2026, strengthens Environmental Risk Assessment at the marketing authorisation level.
Reported by Frederik Dam van Deurs
Legal & Regulatory
Care Pathway Consulting noted that microplastics and antimicrobial resistance markers join the mandatory watchlists.
Reported by Frederik Dam van Deurs
Legal & Regulatory
Care Pathway Consulting noted that Directive 2026/805 entered into force on 11 May 2026.
Reported by Frederik Dam van Deurs
Research & Knowledge
Care Pathway Consulting published a podcast episode featuring Melissa Pegg discussing reusable versus single-use endoscopes, with the Scottish Health Technologies Group providing data on environmental impact, budget impact, and quality-adjusted life year.
Reported by Frederik Dam van Deurs
Legal & Regulatory
Care Pathway Consulting noted that the Environmental Risk Assessment provisions in the EU Pharma Package, due autumn 2026, will fold into the same regulatory picture for pharmaceutical companies.
Reported by Frederik Dam van Deurs
Legal & Regulatory
Care Pathway Consulting noted that Member State transposition by December 2027 and environmental quality standards compliance by 2039 are required for pharmaceutical companies.
Reported by Frederik Dam van Deurs
Legal & Regulatory
Care Pathway Consulting noted that Directive 2026/805 places pharmaceuticals on the EU priority substance list alongside pesticides and PFAS, and adds microplastics and antimicrobial resistance markers to the mandatory watchlists.
Reported by Frederik Dam van Deurs